Case Report

S-100-negative, GNA11 mutation-positive intramedullary meningeal melanocytoma of the thoracic spine: A radiographic challenge and histologic anomaly

Alex Flores1, Ron Gadot1, Ibrahim Noorbhai2, Hayden Hall2, Kent Alan Heck3, Daniel Matthew Sholto Raper1, David Xu1, Patrick Karas1, Jacob J. Mandel2, Alexander Eli Ropper1

Departments of 1Neurosurgery, 2Neurology and 3Pathology, Baylor College of Medicine, Houston, Texas, United States.

E-mail: Alex Flores - alex.flores@bcm.edu; *Ron Gadot - ron.gadot@bcm.edu; Ibrahim Noorbhai - ibrahim.noorbhai@bcm.edu; Hayden Hall - hayden.hall@bcm.edu; Kent Alan Heck - heck@bcm.edu; Daniel Matthew Sholto Raper - daniel.raper@bcm.edu; David Xu - david.xu@bcm.edu; Patrick Karas - patrick.karas@bcm.edu; Jacob J. Mandel - Jacob.mandel@bcm.edu; Alexander Eli Ropper - alexander.ropper@bcm.edu

ABSTRACT

Background: Intramedullary melanocytomas are exceedingly rare and their management is largely based on case reports and small clinical series. They have characteristic imaging and histologic findings that can aid in their diagnosis. Genetic testing may be required for definitive diagnosis and management guidance in ambiguous cases.

Case Description: We present the case of a thoracic intramedullary meningeal melanocytoma in a patient unable to undergo an MRI.

Conclusion: This is the first reported S-100-negative case with genetic testing to support the diagnosis of a rare intramedullary melanocytoma.

Keywords: GNA11 mutation, Intramedullary spinal tumor, Melanocytoma, S-100

INTRODUCTION

Meningeal melanocytomas are extremely uncommon tumors of the central nervous system (CNS) derived from leptomeningeal melanocytes, with only a few published case reports describing their incidence, presentation, and management. The first report in the English literature from 1972 along with a few following reports describes the tumors as occurring along the spine and posterior fossa with peak incidence around the 5th decade of life.1,11,15,23 Melanocytomas fall within a spectrum of melanocytic neoplasms ranging from benign low-grade melanocytomas to those of intermediate and higher grades, to melanomas of either primary or metastatic behavior.6,11,23 They share many immunohistopathological and imaging characteristics with their more malignant melanoma counterparts.14 A growing body of molecular data is helping to classify the genomic landscape of these distinct neoplasms. Cutaneous metastatic melanomas as well as primary melanomas of the CNS often harbor mutations in established oncogenes including BRAF, NRAS, cKIT, and/or TERT promoter.11,13 In contrast, recent literature has suggested that the absence of these aforementioned mutations in the presence of hotspot somatic mutations in the GNAQ gene.
may be specific to melanocytomas.\textsuperscript{11,13,14} Management of melanocytic CNS tumors can vary widely based on diagnosis but is generally aimed at gross total resection with adjuvant radiotherapy due to their high probability of recurrence.\textsuperscript{23}

**CLINICAL PRESENTATION**

A 69-year-old male with atrial fibrillation, history of cardiac arrest status with subsequent implantable cardioverter defibrillator (ICD) placement, and chronic kidney disease presented to the hospital with subacute progressive bilateral leg weakness, a vague lower thoracic sensory level, and both bowel and bladder dysfunction. Beginning 6 months before this, the patient reported loss of temperature sensation in his waist and legs and slowly developed bilateral leg weakness. Weeks before admission, he began experiencing progressive urinary and bowel retention and incontinence. He underwent an extensive outpatient workup including electromyography (EMG), lumbar puncture, and lumbar CT myelogram. EMG and CT myelogram were unremarkable. The only notable finding on initial evaluation was an elevated cerebrospinal fluid protein of 150 mg/dL (anti-NMO, anti-MOG, oligoclonal bands, and ACE all within normal limits). In an attempt to obtain an MRI, his ICD was removed, but unfortunately, the cardiac leads could not be completely recovered. Since an MRI could not be obtained, he was empirically started on dexamethasone, which did not improve his symptoms.

At time of admission, he had 4+/5 strength in all right lower extremity muscle groups, 0/5 L hip flexion, 2/5 L knee extension, decreased sensation below the T10 dermatome, bilateral patellar hyperreflexia, and extensor plantar reflexes bilaterally.

**Hospital management**

Given the subacute presentation of paraparesis with a sensory level, without obvious diagnosis from the spinal fluid, there was a clinical suspicion for a dural arteriovenous fistula. Spinal angiogram was performed, remarkable only for midline subtle vascular congestion at T9 within the cord parenchyma. Intravenous methylprednisolone was begun for concern for transverse myelitis with modest strength improvement and subsequently plasmapheresis with equivocal improvement.

A thoracic CT myelogram was performed revealing what appeared to be an intradural, extramedullary lobulated lesion in the ventral left canal, presumed to be either a superiorly migrated disc extrusion, or an intradural extramedullary spinal tumor. The mass resulted in moderate to severe left-sided central canal stenosis contouring and displacing the cord to the right of midline [Figure 1].

Given the patient’s lack of improvement to empiric treatment and the lack of a diagnosis, he ultimately underwent surgery for biopsy and resection of the mass. This was performed through a midline T8-9 laminectomy and intradural exploration. Intraoperatively, the tumor was located in the lateral subarachnoid space, but not emanated from or attached to the inside of the dura. The mass was originating within the cord parenchyma and had extruded out of the left lateral border of the spinal cord into the intradural, extramedullary space [Figure 2]. Debulking of the intraparenchymal portion was stopped short due to decrements in intraoperative motor and somatosensory evoked potentials. The tumor had no clear and dissectible border from the cord parenchyma.

Pathology of the mass was consistent with a melanocytic tumor, possibly melanoma. Analysis of permanent sample revealed a proliferation of tumor cells found to be relatively bland with no necrosis identified. Melanin production was multifocal. Immunoperoxidase stains were diffusely positive for melanoma cocktail (HMB-45/Tyrosinase/MART-1) but negative for S-100. Immunoperoxidase stains for GFAP,

Figure 1: CT myelogram showing T8/9 lobulated mass that appeared to be intradural, extramedullary, presumed to be superior disc extrusion versus intradural meningioma or nerve sheath tumor.

Figure 2: Intraoperative view of intramedullary portion of thoracic tumor.
AE1/3 were negative. The Ki-67 proliferation index was found to be no higher than 4.1%. Given the very rare mitoses, relatively low proliferation index, and cytologically bland histology, a primary meningeal melanocytoma was favored, but a metastatic melanoma to the spine or primary malignant melanoma could not be excluded.

An outside hospital dermatopathological conference reviewed permanent sections of the tumor and favored diagnosis of melanoma citing conspicuous nuclear and cellular morphologic features as well as areas of focal necrosis and increased proliferation index. Repeat analysis confirmed morphological and immunohistochemical features further supporting intermediate-to-high-grade primary meningeal melanocytoma versus melanoma [Figure 3].

Postoperative workup for an extraspinal primary or metastatic melanoma including dermatological, otolaryngological, and ophthalmological examinations as well as a CT brain/spine/abdomen/pelvis without contrast and PET-CT scan was unremarkable. The patient was discharged to inpatient rehabilitation and discharged from rehabilitation after 3 weeks. Despite worsening strength in the left leg immediately postoperatively, he ultimately regained strength in the left leg to his preoperative baseline with improved right leg strength. No decision has been made regarding pursuing adjuvant radiotherapy, though it has been recommended. Genetic testing (Tempus, Chicago, IL) on permanent sample revealed a GNA11 p.Q209L missense gain-of-function (GOF) mutation and was without mutation in BRAF, NRAS, or KIT genes favoring the diagnosis of meningeal melanocytoma.

DISCUSSION

Melanocytoma is a rare primary spinal tumor with an annual incidence of 1/10 million, representing <0.1% of all CNS tumors.[7] The majority of these tumors arise in the intradural extramedullary compartment.[7] Intramedullary cases, such as this one, are exceedingly rare, with <30 cases reported in literature.[8,26]

Although presentation depends on location of the tumor, workup invariably leads to neuroimaging. MRI represents the modality of choice, especially given the characteristic MRI signature of the melanin pigment.[7,17] Our case presented a unique diagnostic challenge, given the inability to use MRI for workup. Ultimately, CT myelogram revealed the mass warranting surgery. Although the preoperative differential primarily included intradural extramedullary lesions, this case demonstrated the ability of CT myelogram to identify expansile intramedullary spinal cord pathology in the setting of contraindications to MRI.

Between the WHO criteria and a proposition by Brat et al., melanocytomas are divided histologically into low-grade melanocytomas, intermediate-grade tumors, and malignant melanomas.[4,5,16,18,26] Typically, melanocytomas are immunohistochemically positive for S-100 protein and the more specific melanocytic markers HMB-45 and

![Figure 3: Histopathology. (a) Hematoxylin and eosin (H&E) stain, ×40 and (b) ×20 showing a solid proliferation of atypical epithelioid cells with scattered pigmented melanophages amidst fibroconnective tissue. The samples are richly cellular with round to ovoid nuclei and prominent nucleoli. There are areas of necrosis with associated inflammation and hemorrhage. (c) Few spindle-shaped nests of cells admixed with melanophages were noted, ×40. (d) Ki-67 (MIB-1) index seen to be 1.5% with all other areas on ×40 found to be <4%. (e) HMB45/Tyrosinase/MART-1 immunoperoxidase stain diffusely positive, ×40. (f) S-100 immunoperoxidase stain negative with interspersed dusty brown melanin pigment, ×40.]
Melan A (MART-1). By the WHO criteria, low-grade melanocytomas are cytologically bland, solitary neoplasms with low mitotic activity (MIB1 < 1–2%). Malignant melanomas are typically widely infiltrating neoplasms with obvious cytological atypia, high mitotic activity (MIB1 >= 8%), and diffuse necrosis. Intermediate-grade tumors are those with increased mitotic activity that does not meet all characteristic of malignant melanoma.

Concerning the possibility that this tumor could have been a melanoma, much attention was paid to its histopathology. While the tumor stained positively for melanoma cocktail, it stained negatively for S-100 which has been found to be the most sensitive marker for melanomas. This may indicate loss of antigenicity/dedifferentiation. Although S-100 loss of antigenicity has been reported in metastatic melanoma, its loss in primary melanoma is rare. Aisner et al. developed criteria for diagnosing S-100-negative melanomas based on a survey of 1553 patients undergoing National Cancer Institute trials for melanoma. S-100 protein was found to be expressed in 99% of melanomas, consistent with other reports. With a relatively low proliferation index (Ki-67 <= 4.1%) and otherwise only focal areas of locally aggressive behavior (necrosis and mitoses), a diagnosis of melanoma was at best equivocal under the microscope. Based on its immunohistochemical profile and lack of cellular atypia, our case best fell within the category of primary intermediate-grade melanocytoma.

In histologically challenging cases of melanocytomas such as this, molecular profiling has been shown to help differentiate between malignant melanoma and lower-grade primary melanocytomas, with the presence of GNAQ mutation in the absence of typical mutations of cutaneous melanomas including BRAF and NRAS suggesting primary CNS tumor. Interestingly, our patient’s tumor possessed a GOF mutation at codon 209 of the GNA11 gene. GNA11 (G alpha 11) encodes the alpha subunit of a guanine nucleotide-binding protein functioning in calcium regulation processes as well as cellular proliferation and apoptosis. Activating mutations of GNA11 are associated with varied cancer progression, including that of ocular melanocytomas. Hoffmann et al. reported a case of an intramedullary melanocytoma with a Q209L mutation in the GNAQ gene, a nearly identical mutation to the one seen in our patient in a different gene of the same gene family. In the absence of primary lesions or typical mutations of extraspinal melanomas including BRAF, NRAS, and KIT, and combined with suggestive histological findings, our patients profile corresponds well with that of a primary spinal melanocytoma.

Gross total resection is the initial treatment of choice for these tumors as survival is better and local control rates have been shown to be 4 times higher if complete resection is achieved. Rades et al. reported 5-year survival rates of 100% with complete resection with or without adjuvant radiation. Local control is particularly important for these tumors because recurring tumors may transform from meningeal melanocytoma to melanoma and, further, because melanocytomas have been reported to metastasize. In this case, intraoperative loss of motor signals resulted in subtotal resection of the intramedullary tumor. Current literature supports adjuvant radiation therapy for all subtotal resections, resulting in improved local control and survival. In a series of 89 patients, median time to recurrence following incomplete resection (ITR) was 12 months (range, 12–48 months) though in patients in whom malignant transformation or metastases were not observed, such as in our patient, median time to recurrence after ITR was 24 months (range, 3–119 months). Reported regimens include 25–30 treatments of intensity-modulated fractionated radiation therapy, with a total dose of 5040 cGy. Doses >45 Gy have been shown to be beneficial compared to lower doses. In addition, studies have shown that immunomodulator therapy with trametinib has been effective in treating GNA11 p.Q209L GOF-mutated uveal melanomas, though given the rarity of this clinical entity, no similar trials have been undertaken for CNS melanocytomas.

More cases are required to obtain accurate recurrence rates, but authors have noted recurrences to be common. Close radiographic surveillance is warranted. Although there is no standard protocol for follow-up, it has been suggested that surveillance scans be done at regular intervals, with every 6 months as a reasonable rate, based on data reporting a median recurrence at 12 months for metastasizing meningeal melanocytomas. Surveillance will be particularly challenging for this patient given his inability to obtain MRI and relative contraindication to contrast given his renal failure. Close follow-up with serial neurological exams and CT spine without contrast and/or CT myelogram may be considered to optimize outcomes in such cases.

CONCLUSION

We report on a radiologically and histologically challenging case of a thoracic intramedullary melanocytic neoplasm that was determined to be an intermediate-to-high-grade melanocytoma given immunohistochemical and molecular analysis. Although rarely used since the advent of MRI, CT myelogram should be considered as a diagnostic means for a differential that includes expansile intramedullary lesions in the setting of contraindications to MRI. In the absence of confirmed primary melanotic tumors, mutational analysis of suggestive genetic loci including GNA11, GNAQ, BRAF, NRAS, and cKIT can be useful in definitive diagnosis and management.
Declarations of patient consent

Patient's consent not required as patients identity is not disclosed or compromised.

Financial support and sponsorship

Nil.

Conflicts of interest

There are no conflicts of interest.

REFERENCES

1. Aisner DL, Maker A, Rosenberg SA, Berman DM. Loss of S100 antigenicity in metastatic melanoma. Hum Pathol 2005;36:1016-9.
2. Argenyi ZB, Caim C, Bromley C, Nguyen AV, Abraham AA, Kerschmann R, et al. S-100 protein-negative malignant melanoma: Fact or fiction? A light-microscopic and immunohistochemical study. Am J Dermatopathol 1994;16:233-40.
3. Biernacka A, Linos KD, DeLong PA, Suriawinata AA, Padmanabhan V, Liu X. A case of S-100 negative melanoma: A diagnostic pitfall in the workup of a poorly differentiated metastatic tumor of unknown origin. Cytojournal 2016;13:21.
4. Brat DJ, Giannini C, Scheithauer BW, Burger PC. Primary melanocytic neoplasms of the central nervous system. Am J Surg Pathol 1999;23:745-54.
5. Brat DJ, Parisi JE, Kleinschmidt-DeMasters BK, Yachnis AT, Montine TJ, Boyer PJ, et al. Surgical neuropathology update: A review of changes introduced by the WHO classification of tumours of the central nervous system, 4th edition. Arch Pathol Lab Med 2008;132:993-1007.
6. de Potter P, Shields CL, Eagle RC Jr., Shields JA, Lipkowitz JL. Malignant melanoma of the optic nerve. Arch Ophthalmol 1996;114:608-12.
7. Dorwal P, Mohapatra I, Gautam D, Gupta A. Intramedullary melanocytoma of thoracic spine: A rare case report. Asian J Neurosurg 2014;9:36-9.
8. Dubey A, Kataria R, Sardana VR. Intramedullary melanocytoma. Rare Tumors 2010;2:e24.
9. Eskandari R, Schmidt MH. Intramedullary spinal melanocytoma: Diagnostic criteria for a rare lesion. Neurosurgery 1992;31:945-8.
10. Faler MA, Lewis KD, Infante JR, Gordon MS, Vogelzang NJ, DeMarini DJ, et al. Activity of the oral MEK inhibitor trametinib in patients with advanced melanoma: A phase I dose-escalation trial. Lancet Oncol 2012;13:782-9.
11. Hoffmann M, Koelsche C, Seiz-Rosenhagen M, Mai S, Lohr F, Reuss D, et al. The GNAQ in the haystack: Intramedullary meningeal melanocytoma of intermediate grade at T9-10 in a 58-year-old woman. J Neurosurg 2016;125:53-6.
12. Horn EM, Nakaji P, Coons SW, Dickman CA. Surgical treatment for intramedullary spinal cord melanocytomas. J Neurosurg Spine 2008;9:48-54.
13. Koelsche C, Hovestadt V, Jones DT, Capper D, Sturm D, Sahm F, et al. Melanotic tumors of the nervous system are characterized by distinct mutational, chromosomal and epigenomic profiles. Brain Pathol 2015;25:202-8.
14. Küsters-Vandevelde HV, Klaasen A, Küsters B, Groenen PJ, van Engen-van Grunsven IA, van Dijk MR, et al. Activating mutations of the GNAQ gene: A frequent event in primary melanocytic neoplasms of the central nervous system. Acta Neuropathol 2010;119:317-23.
15. Limas C, Tio FO. Meningeal melanocytoma ("melanotic meningioma"). Its melanocytic origin as revealed by electron microscopy. Cancer 1972;30:1286-94.
16. Litofsky NS, Zee CS, Breeze RE, Chandrasoma PT. Meningeal melanocytoma: Diagnostic criteria for a rare lesion. Neurosurgery 1992;31:433-44.
17. Merhemic Z, Stocic-Opinical T, Thornher MM. Neuroimaging of spinal tumors. Magn Reson Imaging Clin N Am 2016;24:563-79.
18. O'Brien TF, Moran M, Miller JH, Hensley SD. Meningeal melanocytoma. An uncommon diagnostic pitfall in surgical neuropathology. Arch Pathol Lab Med 1995;119:542-6.
19. Ohsie SJ, Sarantopoulos GP, Cochran AJ, Binder SW. Immunohistochemical characteristics of melanoma. J Cutan Pathol 2008;35:433-44.
20. Parish AJ, Nguyen V, Goodman AM, Murugesan K, Freampton GM, Kurzrock R. GNAS, GNAQ, and GNA11 alterations in patients with diverse cancers. Cancer 2018;124:4080-9.
21. Rades D, Heidenreich F, Tatagiba M, Brandis A, Karstens JH. Therapeutic options for meningeal melanocytoma. Case report. J Neurosurg 2001;95 Suppl 2:225-31.
22. Rades D, Schild SE. Dose-response relationship for fractionated irradiation in the treatment of spinal meningeal melanocytomas: A review of the literature. J Neurooncol 2006;77:311-4.
23. Rades D, Schild SE, Tatagiba M, Molina HA, Alberti W. Therapy of meningeal melanocytomas. Cancer 2004;100:2442-7.
24. Rades D, Tatagiba M, Brandis A, Dubben HH, Karstens JH. The value of radiotherapy in treatment of meningeal melanocytoma. Strahlenther Onkol 2002;178:336-42.
25. Shinohara MM, Deubner H, Argenyi ZB, S100, HMB-45, and melan-a negative primary melanoma. Dermatol Online J 2009;15:7.
26. Shimizu K, Nakamura H, Ueda T, Tanaka T, Kato K, et al. GNA11 mutation-positive intramedullary meningeal melanocytoma of the thoracic spine: A radiographic challenge and histologic anomaly. Surg Neurol Int 2020;12:315.

How to cite this article: Flores A, Gadot R, Noorbhai I, Hall H, Heck KA, Raper DM, et al. S-100-negative, GNA11 mutation-positive intramedullary meningeal melanocytoma of the thoracic spine: A radiographic challenge and histologic anomaly. Surg Neurol Int 2020;12:315.